20 Feb 2020
Denise Swift, senior scientist at Sygnature Discovery, discusses how high-throughput screening (HTS) was established at Sygnature Discovery in Nottingham, U.K.. HTS was introduced to complement its existing suite of hit-finding approaches and offer a more comprehensive integrated hit-discovery platform to enhance successful early drug discovery for their clients.
Sygnature Discovery
After graduating with a master's in molecular biology from Leicester University, Denise Swift worked for a year at Axis Genetics before joining pharma giant AstraZeneca as a senior research scientist. She moved to Sygnature Discovery as senior scientist in 2012.